PepGen has been awarded a grant of £1.6 M from Innovate UK, the UK’s innovation agency.
The company’s project, entitled ‘Application of a novel peptide delivery platform to nucleic acid therapeutics in degenerative and rare diseases’, will run for 20 months, and this funding will be instrumental in supporting the pre-clinical development of PepGen’s innovative technology.
PepGen’s grant from Innovate UK falls within the Biomedical Catalyst Early Stage Award. This scheme aims to create a sufficient data package to support the testing of a product in a clinical setting. The Biomedical Catalyst is highly competitive, and the company’s success in this award has provided additional validation of the potential impact that PepGen’s technology could have on disease areas of great unmet need.